The combination of Ruxolitinib and GSK-LSD1 was further tested for its efficiency to reverse the expression of anti- and pro-apoptotic proteins (BCL2 & BIM) in Zeb2Tg ETP-ALL. Here, BCL2L11 is linked to acute lymphoblastic leukemia.